Paul Little | BiotechTV

top of page

BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines

CEO Paul Little talks about the benefits of muscle strength and mass, and why Atrogi thinks beta-2 agonism is a good way to improve it - and why he believes their approach has engineered any potential safety issues out. Coverage brought to you by:

Company News

2 minutes ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page

BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines

Follow BiotechTV

Sponsors

Sponsor Spotlight